SIK3
| Official symbol: | SIK3 |
| Full name: | SIK family kinase 3 |
| Location: | 11q23.3 |
| Also known as: | KIAA0999, FLJ12240, L19, QSK |
| Entrez ID: | 23387 |
| Ensembl ID: | ENSG00000160584 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 1.05 (Driver) |
|
|
|
| Recurrently deleted in 5 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 6 |
|
|
| Fusions detected in 5 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
CRISPR: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 18.17 (Percentile rank: 45.82%) |
| PubTator score: | 4.16 (Percentile rank: 25.97%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | |
